Figure 1:
Figure 1:. FFS CMR versus no CMR by landmark analysis for pts who received at least 24.0 months of nilotinib

FFS CMR versus no CMR by landmark analysis for pts who received at least 24.0 months of nilotinib

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal